I think you’ll find a few of us in here who have been around a while and have a thorough understanding of what the company is trying to achieve. From that understanding, some are quite confident that the upcoming Ph2B will yield statistically and clinically significant results.
But still: fingers crossed, and GLTAH.
General Discussion, page-60
-
- There are more pages in this discussion • 75 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.0¢ |
Change
-0.010(2.04%) |
Mkt cap ! $269.6M | |||
| Open | High | Low | Value | Volume |
| 49.5¢ | 49.5¢ | 48.0¢ | $134.0K | 273.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 47766 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.5¢ | 42335 | 4 |
View Market Depth
| Last trade - 10.13am 15/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |